A post-hoc analysis from SHIFT assessed the impact of ivabradine on early readmissions in patients hospitalized for heart failure. Ivabradine significantly reduced the risk of early recurrent hospitalizations following a first heart failure hospitalization. This reduction of risk was significant from the first month onwards (30% relative risk reduction, P<0.05), ranging from 21% to 30% within the first 3 months following a heart failure hospitalization.
Komajda M, Tavazzi L, Swedberg K, et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. Eur J Heart Fail. 2016;18(9):1182-1189.